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the original work isBackground: Cardiovascular disease and non-AIDS malignancies have become major
causes of death among HIV-infected individuals. The relative impact of lifestyle and
HIV-related factors are debated.
Methods: We estimated associations of smoking with mortality more than 1 year after
antiretroviral therapy (ART) initiation amongHIV-infected individuals enrolled in European
and North American cohorts. IDUs were excluded. Causes of death were assigned using
standardized procedures. We used abridged life tables to estimate life expectancies. Life-
years lost to HIV were estimated by comparison with the French background population.
Results: Among 17995 HIV-infected individuals followed for 79760 person-years, the
proportion of smokers was 60%. Themortality rate ratio (MRR) comparing smokers with
nonsmokers was 1.94 [95% confidence interval (95% CI) 1.56–2.41]. The MRRs
comparing current and previous smokers with never smokers were 1.70 (95% CI
1.23–2.34) and 0.92 (95% CI 0.64–1.34), respectively. Smokers had substantially
higher mortality from cardiovascular disease, non-AIDS malignancies than nonsmokers
[MRR 6.28 (95%CI 2.19–18.0) and 2.67 (95%CI 1.60–4.46), respectively]. Among 35-
year-old HIV-infected men, the loss of life-years associated with smoking and HIV was
7.9 (95% CI 7.1–8.7) and 5.9 (95% CI 4.9–6.9), respectively. The life expectancy of
virally suppressed, never-smokers was 43.5 years (95% CI 41.7–45.3), compared with
44.4 years among 35-year-old men in the background population. Excess MRRs/1000
person-years associated with smoking increased from 0.6 (95%CI –1.3 to 2.6) at age 35
to 43.6 (95% CI 37.9–49.3) at age at least 65 years.
Conclusion: Well treated HIV-infected individuals may lose more life years through
smoking than throughHIV. Excessmortality associatedwith smoking increasesmarkedly
with age. Therefore, increases in smoking-relatedmortality can be expected as the treated
HIV-infected population ages. Interventions for smoking cessation should be prioritized.
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To target health interventions where they are most
needed, it is necessary to evaluate which risk factors are
major contributors to loss of potential life years. The
contribution of risk factors to the global burden of disease
has shifted from communicable towards noncommunic-
able diseases, and tobacco smoking was the leading risk
factor for disease burden in North America and Western
Europe in 2010 [1].
Morbidity and mortality among people living with HIV
decreased substantially after the introduction of combi-
nation antiretroviral therapy (ART) in 1996 [2,3]. With
the decline in AIDS mortality, cardiovascular diseases
(CVDs) and non-AIDS malignancies have become major
causes of death in the HIV-infected population [4–7].
All-cause mortality as well as the risk of non-AIDS related
death continues to be higher among HIV-infected
individuals than among the background population
[8,9]. The relative contributions of immune deficiency,
inflammation, cumulative toxicities of long-term ART
and lifestyle to mortality in HIV-infected individuals
remain unclear [10,11].
A recent study [12] in Denmark found that more than
60% of deaths in the HIV-infected population were
associated with smoking, and that the number of life years
lost in association with smoking was larger than that
associated with HIV-related factors among 35-year-old
HIV-infected smokers. We hypothesized that these results
can be generalized to Western Europe and North
America and that smoking and lifestyle-associated factors
may contribute more to excess mortality in the treated
HIV-infected population than factors related to HIV. The
aims of the present study were to estimate associations of
smoking with all-cause and cause-specific mortality and
to estimate loss of life years associated with smoking,
among HIV-infected individuals treated in Western
Europe and North America. Furthermore, we aimed
to assess whether the association between smoking and
mortality differ by age or immune status.Materials and methods
Participants
The ART Cohort Collaboration (ART-CC) is an
international collaboration between the investigators of
cohort studies of HIV-1 positive individuals from Europe
and North America, described in detail elsewhere [13]and at www.art-cohort-collaboration.org. Prospective
cohort studies were eligible to participate if they had
enrolled at least 100 HIV-1 positive individuals aged at
least 16 years who had not previously received ART,
started ART with a combination of at least three
antiretroviral drugs and had a median duration of
potential follow-up of at least 1 year after ART initiation.
All cohorts provided anonymized data on a predefined set
of demographic, laboratory and clinical variables, which
were then pooled and analysed centrally. The dataset
analysed here included data from eight cohorts, which are
listed in the web appendix. The numbers of individuals
included in the present study from each cohort are
summarized in supplementary table 2, http://links.lww.-
com/QAD/A608. The NHS Health Research Authority
South West, Cornwall and Plymouth Research Ethics
Committee, UK, approved the study (REC reference 12/
SW/0253).
Participant selection and data collection
Individuals were eligible for inclusion in this analysis if
they started ART between 1 January 1996 and 1
December 2008, were alive and under follow-up 365
days after initiation of ART, and data on smoking status
were available. Follow-up time started (baseline) at the
latest of first date of ascertainment of smoking status or
365 days after ART initiation, by which time CD4þ cell
counts have usually risen substantially, with correspond-
ing declines in AIDS-related mortality [7,14,15].
Individuals whose transmission was via injection drug
use were excluded, because the vast majority are smokers
and because they experience high mortality due to
comorbidities and other nonsmoking risk factors [16].
Thus, if IDUs were included in analyses, there would be a
risk of overestimating the impact of smoking on mortality.
Information on mortality was obtained either through
linkage with Vital Statistics agencies and hospitals or
through physician report and active follow-up of cohort
participants. We adapted the Cause of Death (CoDe)
project protocol [17] (www.cphiv.dk/CoDe.aspx) to
classify causes of death. We used a computer algorithm
developed by the Mortalite´ 2000–2005 Study Group [18]
to classify deaths wherein ICD10 codes were available.
These classifications were compared with those coded by
a clinician. When ICD10 codes were not available, two
clinicians independently classified each death. Disagree-
ments between clinicians and/or computer-assigned
codes were resolved via panel discussion, as described
previously [7]. Deaths were coded as AIDS-related if
there was a serious AIDS-defining condition(s) close to
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prior to death and a diagnosis compatible with AIDS as a
cause of death. All other deaths, including deaths of
unknown cause, were considered non-AIDS related.
The exposure of interest was tobacco smoking. Individ-
uals were categorized as smokers (current or previous
smokers) or nonsmokers on the basis of information on
smoking status at baseline and did not change category
during the observation period. More detailed data were
available on a subgroup of patients from five cohorts,
enabling categorization of individuals as current, previous
or never smokers.
Statistical methods
Follow-up time was calculated from baseline until date of
death, loss to follow-up, 180 days after last clinical follow-
up or 31 December 2009, whichever came first. Excess
mortality rates were estimated using the formula:
MRunexposed – MRexposed. Mortality rate ratios (MRRs)
were estimated using Poisson regression adjusted for sex,
age (in 2-year intervals), route of HIV transmission,
CD4þ cell count at baseline, year of ART initiation, years
on ART (time-updated in 1-year intervals) and AIDS at
ART initiation.
We used abridged life tables to estimate life expectancies
among men: there were too few deaths among
nonsmoking women to provide meaningful estimates.
Abridged life tables describe the mortality that hypothe-
tical cohorts of HIV-infected individuals would have if
they were subject to the age-specific mortality rates
observed during follow-up. Further details on estimating
life expectancy have been described previously [19]. Age-
specific mortality rates were calculated for ages 25–65
years in 10-year intervals. Deaths and observation time
were pooled for those above 65 years of age. Mortality
rates among HIV-infected men were compared with the
corresponding mortality rates from the male French
general population (www.mortality.org), under the
assumption that the French population was representative
for Western Europe and North America. In these
analyses, the mortality rates of the HIV-infected
population were adjusted to the sex-specific smoking
frequency in the French population by weighted averages.
At ages above 65 years, data were sparse and mortality
rates were adjusted, assuming that the MRR of
individuals aged at least 65 years compared with those
aged 55–65 years was at least 50% of the corresponding
MRR in the general French population. In sensitivity
analyses, we assumed that the mortality rate of individuals
in the HIV population aged at least 65 years was 20%
higher and 20% lower than that of the primary analysis.
Numbers of life years lost were estimated by subtraction
of the age-specific life expectancy of the exposed from
that of the unexposed. Stata statistical software, Version
11.0 (StataCorp, College Station, Texas, USA) and
Microsoft Excel 2007 were used for data analysis.Role of funding sources
The funding sources were not involved in study design,
collection, analysis or interpretation of data, in writing of
the report or in the decision to submit the article
for publicationResults
Participants
Of 45 812 eligible HIV-infected individuals in the eight
participating cohorts, 3567 were excluded due to IDU and
24 250were excluded due to lackof data on smoking status,
leaving 17 995 individuals in the study who were followed
for a total of 79 760 person-years. The proportion of men
was 71.3%; 70.6% had viral load less than 400 copies/ml
and 56.2% had CD4þ cell count more than 350 cells/ml at
baseline (Table 1). Compared with nonsmokers, the
median age of smokers was 2 years older, the proportion of
MSM was higher and duration of ART at baseline was
longer. In three of the participating cohorts, individuals
were categorized as smokers or nonsmokers (n¼ 9476;
46 777 person-years), and in five of the cohorts, individuals
were categorized as current, previous or never smokers
(n¼ 8519; 32 983 person-years). Comparing individuals
who were excluded with those included in the study, the
proportion of men was lower (66.3 versus 71.3%), a higher
proportion was aged more than 50 years at ART initiation
(17.9 versus 14.1%) and a higher proportion died during
follow-up (7.8 versus 2.9%), (supplementary table 1,
http://links.lww.com/QAD/A608).
Risk of death among smoking compared with
nonsmoking HIV-infected individuals
Rates of all-cause mortality were 7.9 [95% confidence
interval (95% CI) 7.2–8.79] per 1000 person-years among
smokers and 4.2 (95% CI 3.5–5.0) among nonsmokers; the
adjusted MRR comparing smokers with nonsmokers was
1.94 (95% CI 1.56–2.41). MRRs comparing smokers with
nonsmokers were similar within strata defined by sex,
calendar period, route of HIV transmission, immune status
or viral suppression at baseline (Table 2). Among individuals
with more detailed smoking data available (n¼ 8519), the
proportions of current, previous and never smokers were
46.5, 25.7 and 27.8%, respectively. The MRR among
current versus never smokers was 1.70 (95% CI 1.23–2.34)
and that of previous versus never smokers was 0.92 (95% CI
0.64–1.34).
Non-AIDS related deaths
Causes of death could be classified in 452 of 520 cases
(90%), of which 152 (29%) were classified as AIDS-
related [mortality rate 1.6 per 1000 person-years (95% CI
1.3–1.9)]. The remaining 368 deaths (71%) were
considered non-AIDS related [mortality rate 4.6 per
1000 person-years (95% CI 4.2–5.1)]. Rates of non-
AIDS related death were increased among smokers
compared with nonsmokers [MRR 2.61 (95% CI
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Table 1. Characteristics of the study population at baseline (>–1 year after start of antiretroviral therapy), n (%).
Smokers Nonsmokers Pc
n 10767 7228
Observation time (years) 49688 30072
Follow-up time (years)a 4.3 (1.9–7.3) 3.7 (1.6–6.1)
Deaths 393 127
Year of study inclusiona 2003 (2001–2006) 2004 (2002–2007) <0.01
Males 8689 (80.7) 4143 (57.3) <0.01
Age at baseline (years)a 40 (34–47) 38 (32–46) <0.01
<35 3046 (28.3) 2581 (35.7)
35–50 5565 (51.7) 3307 (45.8)
>50 2156 (20.0) 1340 (18.5)
Route of HIV infection
MSM 4830 (44.9) 2152 (29.8) <0.01
Heterosexual male 2746 (25.5) 1476 (20.4)
Heterosexual female 1906 (17.7) 2852 (39.5)
Other 1285 (11.9) 748 (10.4)
AIDS at baseline 2539 (23.6) 1666 (23.1) 0.66
CD4þ cell count (cells/ml)a,b 426 (272–614) 390 (254–540) <0.01
<200 1451 (13.5) 1032 (14.3)
200–349 2279 (21.2) 1760 (24.4)
350–500 2371 (22.0) 1831 (25.3)
>500 3861 (35.9) 2039 (28.2)
Viral load <400 copies/ml 7759 (72.1) 4952 (68.5) <0.01
Duration of ART at baseline (years)
1 7449 (69.2) 6075 (84.1) <0.01
1–2 764 (7.1) 276 (3.8)
2–5 1729 (16.0) 540 (7.5)
>5 825 (7.7) 337 (4.7)
aMedian (interquartile range).
bAt baseline, missing data: CD4þ cell count: 1371cells/ml (7.6); viral load: 1486copies/ml (8.3).
cMann–Whitney rank sum test for continues data and chi-square test for categorical variables.1.88–3.61)] (Table 3). Rates of death caused by CVD,
non-AIDS malignancy and liver disease were substantially
higher among smokers than among nonsmokers [MRR
6.28 (95% CI 2.19–18.0), 3.13 (95% CI 1.80–5.45) and
8.70 (95% CI 1.14–66.6), respectively]. The relative risks
of death from CVD, non-AIDS malignancies, infections
and liver disease comparing current with never smokers
were higher than the relative risks comparing previous
with never smokers (Table 3).
Deaths from non-AIDS malignancies
In supplementary table 3, http://links.lww.com/QAD/
A608 deaths caused by non-AIDS malignancies are
displayed according to cancer site. The proportion of
non-AIDS malignant deaths that was caused by lung
cancer was 36%. Thirty-four smokers and no nonsmokers
died of lung cancer. Of the 94 non-AIDS malignant
deaths, 47 (50%) were caused by cancer types strongly
related to smoking (lung, head-and-neck, oesophagus,
pancreas and bladder cancer) and 45 (96%) of these
occurred among smokers.
Life expectancies and life years lost
Among 35-year-old HIV-infected men, smokers lost 7.9
(95% CI 7.1–8.7) potential life years compared with
nonsmokers (Table 4). The life expectancy of 35-year-oldHIV-infected men was on average 5.9 (95% CI 4.9–6.9)
years shorter than that of 35-year-old men in the
background population after adjusting for smoking in the
background population. At age 65 years, the loss of life
years associated with smoking was 6.6 (95% CI 6.0–7.2)
years, whereas that associated with HIV was only 2.9
(95% CI 2.1–3.7) years. Among 35-year-old HIV-
infected individuals with CD4þ cell count at least
200 cells/ml or viral load less than 400 copies/ml at
baseline, the loss of life years associated with HIV was 3.0
(95% CI 2.0–4.0) and 4.0 (95% CI 2.4–5.6) years,
respectively, while that associated with smoking was 5.6
(95% CI 4.8–6.4) and 8.5 (95% CI 6.9–10.1) years.
Excess mortality rates associated with smoking
and HIV-related factors
Excess mortality rates associated with smoking and HIV-
related factors increased with age (Fig. 1). However, the
increase in excess mortality rates with age was
substantially higher in association with smoking than
HIV-related factors. In the younger age groups, the excess
mortality rate associated with smoking was limited, but
due to the high excess mortality rate at older age, young
smokers had a substantially shorter life expectancy than
nonsmokers. In the older age groups, HIV-related factors
contributed only little to loss of potential life years.
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Table 2. Mortality rates and mortality rate ratios comparing smokers with nonsmokers.
Observation
time (years) Deaths
MR/1000 person-years
(95% CI) MRRa (95% CI)
Smokers versus
NonsmokersSmokers Nonsmokers
All 79760 520 7.9 (7.2–8.7) 4.2 (3.5–5.0) 1.94 (1.56–2.41)
Males 58042 451 8.8 (7.9–9.7) 5.6 (4.6–6.8) 1.84 (1.45–2.34)
Females 21718 69 4.4 (3.2–5.9) 2.2 (1.5–3.3) 2.41 (1.43–4.08)
Study period of follow-up
1996–2004 29728 155 6.2 (5.2–7.4) 3.3 (2.3–4.6) 2.06 (1.36–3.12)
2005–2006 21879 152 8.2 (6.8–9.9) 4.8 (3.5–6.6) 1.75 (1.18–2.61)
2007–2009 28153 213 9.8 (8.4–11.5) 4.6 (3.6–6.0) 2.00 (1.43–2.81)
Route of HIV transmission
MSM 32272 162 5.6 (4.7–6.6) 3.6 (2.6–5.1) 2.10 (1.39–3.19)
Heterosexual males 18817 150 9.7 (8.1–11.6) 4.7 (3.3–6.7) 2.19 (1.44–3.35)
Heterosexual females 20018 57 4.3 (3.1–5.8) 1.7 (1.1–2.7) 3.07 (1.68–5.61)
Other/unknown 5894 59 19.8 (16.4–23.9) 13.6 (10.1–18.2) 1.31 (0.89–1.92)
Age
<35 years 26456 74 3.1 (2.4–4.2) 2.3 (1.6–3.4) 1.71 (0.85–3.42)
35–50 years 38840 226 7.0 (6.0–8.1) 3.8 (2.9–4.9) 1.77 (1.27–2.48)
> 50 years 14465 220 18.7 (16.1–21.7) 9.3 (7.0–12.3) 2.14 (1.55–2.95)
AIDS or CD4þ cell count <200cells/mlb 24963 276 13.6 (11.9–15.6) 7.1 (5.6–9.0) 1.91 (1.42–2.59)
No AIDS and CD4þ cell count 200 cells/mlb 54797 244 5.4 (4.7–6.2) 2.9 (2.2–3.7) 1.90 (1.38–2.61)
Viral load 400copies/mlb 51611 296 6.9 (6.0–7.8) 3.7 (2.9–4.7) 2.01 (1.51–2.66)
Viral load >400copies/mlb 22598 168 9.4 (7.9–11.1) 4.6 (3.4–6.3) 1.94 (1.35–2.79)
Viral load missingb 5551 56 12.5 (9.2–17.0) 6.6 (4.0–10.9) 0.71 (0.19–2.60)
MR, mortality rate; MRR, mortality rate ratio.
aAdjusted for sex, age (time-updated), CD4þ cell count at baseline, route of HIV transmission, AIDS at ART initiation, years on ART (time-updated)
and calendar year of ART.
bAt baseline.Sensitivity analyses
Due to the limited observation time of individuals aged at
least 65 years, we examined the robustness of estimates of
life expectancies and life years lost in association with
smoking in sensitivity analyses wherein the mortality rates
of this age group was set 20% lower (model 1) and 20%
higher (model 2) than the primary analyses. In these
analyses, life expectancies varied by 2–4 years and life
years lost in association with smoking varied by 1–2 yearsTable 3. Cause-specific adjusted mortality rate ratios by smoking status.
All cohorts (79 760 per
years follow-up)
Deaths
MRR (95%
Smoker v
nonsmo
AIDS-related deaths 152 1.37 (0.93
Non-AIDS related deaths 276 2.61 (1.88
Non-AIDS malignancies 94 3.13 (1.80
Cardiovascular disease 39 6.28 (2.19
Non-AIDS infections 26 2.38 (0.88
Liver disease 19 8.70 (1.14
Other 66 1.42 (0.81
Non-AIDS, not classified 32 2.56 (0.96
Accident/violence/suicide/substance abuse 36 2.30 (0.92
Unknown 56 1.38 (0.78
MRRs adjusted for sex, age (time-updated), route of transmission, CD4þ cell
and calendar year of ART. MRR, mortality rate ratio.compared with the primary analyses (supplementary
table 4, http://links.lww.com/QAD/A608).Discussion
In a large collaborative HIV cohort study including
European and North American HIV-infected individuals
who had been on ART for at least 1 year, smoking wasson- Cohorts with information on current, previous and
never-smokers (32 983 person-years follow-up)
CI)
ersus
ker Deaths
MRR (95% CI)
Current versus
never smoker
MRR (95% CI)
Previous versus
never smoker
–2.02) 99 1.21 (0.73–2.01) 0.54 (0.28–1.03)
–3.61) 153 2.45 (1.49–4.03) 1.40 (0.81–2.42)
–5.45) 43 2.42 (1.03–5.68) 0.94 (0.34–2.64)
–18.0) 27 8.82 (1.15–67.8) 4.55 (0.55–37.6)
–2.46) 10 3.98 (0.47–15.8) 1.38 (0.12–15.8)
–66.6) 14 3.44 (0.42–28.4) 1.46 (0.15–14.4)
–2.49) 29 1.08 (0.40–2.93) 0.66 (0.22–1.98)
–6.83) 30 1.90 (0.61–5.96) 2.34 (0.73–7.43)
–5.77) 24 2.14 (0.60–7.60) 0.38 (0.06–2.36)
–2.46) 25 0.93 (0.30–2.87) 1.27 (0.41–3.92)
count at baseline, AIDS at ART initiation, years on ART (time-updated)
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Table 4. Life expectancies and potential life years lost among HIV-infected men in association with smoking and HIV-related factors [years (95%
confidence interval)].
Life expectancy Life years lost
Nonsmokers Smokers All All, adjusteda Smoking
HIV-related
factorsb
Age 35 years 41.4 (40.4–42.4) 33.5 (32.9–34.1) 35.3 (34.7–35.9) 38.6 (37.6–39.6) 7.9 (7.1–8.7) 5.9 (4.9–6.9)
Age 65 years 16.1 (15.1–17.1) 9.5 (8.9–10.1) 10.9 (10.3–11.5) 13.7 (12.9–14.5) 6.6 (6.0–7.2) 2.9 (2.1–3.7)
Age 35, CD4þ cell
count 200cells/ml
43.4 (42.3–44.3) 37.8 (37.0–38.6) 39.3 (38.7–39.9) 41.4 (40.4–42.4) 5.6 (4.8–6.4) 3.0 (2.0–4.0)
Age 35, VL <400
copies/ml
43.5 (41.7–45.3) 35.0 (34.2–35.8) 36.3 (35.7–36.9) 40.4 (38.8–42.0) 8.5 (6.9–10.1) 4.0 (2.4–5.6)
VL, viral load.
aIf smoking frequency equal to the French male background population (36% smokers).
bLife expectancy of the HIV population adjusted for smoking frequency compared with the background population in France (age 35: 44.4; age 65:
16.6).associated with a two-fold increase in mortality. Deaths
from non-AIDS related malignancies and CVD accounted
for most of the excess mortality among smokers. More than
one-third of all non-AIDS related malignant deaths were
from lung cancer and all deaths from lung cancer were in
smokers. The life expectancy of smokers was on average
8 years less than that of nonsmokers: the life expectancy of
nonsmoking 35-year-old men with CD4þ cell count more
than 200 cells/ml or viral suppression at least 1 year after
starting ART was similar to that of the background
population. Excess mortality rates associated with smoking
increased substantially with age. At age 65 years, the loss of
life years associated with smoking was 7 years, while that
associated with HIV-related factors was only 3 years. The
finding of a markedly lower risk of death among previous
compared with current smokers points towards potential
benefits of including smoking cessation interventions in
HIV care.
We included individuals from North America and
Western Europe who had been on ART for at least50
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the loss of life years associated with HIV. We did not have
statistical power to estimate life expectancies among
women, and therefore, the results on life expectancies and
loss of life years can only be generalized to the male HIV-
infected population.
The main limitation of the study is the exclusion of a large
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smokers and nonsmokers. Mortality rates were higher
among excluded than included individuals, which is
likely to result in underestimation of the absolute risk
associated with smoking. However, estimates did not
differ importantly in analyses including only individuals
from the Swiss HIV Cohort, wherein the proportion of
participants with known smoking status was highest
(96%) or individuals from the Veteran Aging Cohort,
wherein data on smoking status were collected at
random (data not shown). There was only limited
observation time of individuals aged at least 65 years,
which may influence the precision of estimates of life
expectancies. In sensitivity analyses assuming 20%
higher or 20% lower mortality rates in this age group,
we found that the estimates of numbers of life years lost
in association with smoking varied by 1–2 years
compared with primary analyses.
We estimated the impact of ever smoking at baseline
rather than including smoking as a time-updated variable.
Few individuals start smoking during middle or old age
and many of the adverse effects of smoking only manifest
after several years of exposure. The risk of death associated
with smoking declines gradually after smoking cessation.
In an HIV-negative population, it was found that
although the increase in risk of death among previous
smokers compared with never smokers declined over
time since smoking cessation, an increase in risk persisted
for up to 19 years [24]. Median follow-up time in the
present study was approximately 4 years, and thus change
in smoking status for a presumably very small proportion
of the study population during the study period is
unlikely to change the estimates significantly.
We did not have data on current versus previous smoking
from all participating cohorts. In the subgroup of
individuals wherein differentiation was possible, previous
smokers had similar mortality to never smokers, which is
in agreement with findings from previous studies [12,23].
We were unable to directly assess the impact of smoking
cessation on life expectancy, but another study found that
the incidence of CVD in HIV patients who stopped
smoking during follow-up decreased substantially with
increased time since smoking cessation [25]. This shows
the importance of implementing smoking cessation
programmes in the HIV-infected population. Training
programmes for HIV physicians in smoking cessation
counselling may increase rates of smoking cessation
among HIV-infected individuals [26].
Adverse effects of tobacco are unlikely to be the only
cause of the higher mortality among smokers than
nonsmokers: it is likely that unmeasured confounders,
such as alcohol intake and other lifestyle-related factors,
contributed to the reduced life expectancy among
smokers. Such factors are likely to explain the substantially
greater rates of liver-related mortality in smokers thannonsmokers. CD4þ cell counts and the proportion with
viral suppression at baseline were similar in smokers and
nonsmokers, and thus our data do not indicate that
smoking is associated with poor HIV control among
individuals without injection drug use. In order to estimate
the loss of life years associated with being HIV-infected, we
compared life expectancies of the HIV-infected population
with the French background population. The HIV-
infected population differ from the background population
not only regarding immune deficiency, immune activation
and exposure to ART but also in relation to lifestyle and
socio-economic status. Thus, in the era of effective ART,
the risk associated with ‘being HIV-infected’ reflects a
complex of several risk factors.
The findings of the present study are in line with results of a
recent study examining mortality associated with smoking
in the HIV-infected population in Denmark [12]. Estimates
of the relative risk of death and the numbers of life years lost
in association with smoking were somewhat lower in the
present study. This may be explained by the fact that we
examined the impact of ever rather than current smoking in
the present study. Furthermore, the median time from start
of ART to study inclusion was shorter and the study
population was younger. The mortality in the HIV-infected
population is high during the first 2 years after start of ART
because of high rates of AIDS-related deaths among late
presenters [14,15].
Due to the increase in life expectancy of HIV-infected
individuals and the reduction in life years lost to AIDS
since the introduction of combination ART [19,27], the
impact of smoking and other lifestyle-associated risk
factors among HIV-infected individuals is likely to have
increased over time concomitantly with ageing of the
HIV-infected population. Studies conducted in the pre
and early ARTera found no association between smoking
and mortality [28–30], although more recent studies have
shown that smoking is associated with increased
morbidity and mortality [23,25,31,32].
We found no indication of interaction between immune
deficiencyand smoking.The relative riskof death associated
with smoking was similar in individuals with high and low
CD4þ cell counts at baseline, but due to the higher
mortality rate among individuals with low CD4þ cell
counts, the absolute risk associated with smoking is much
higher in this group. Due to the lack of an HIV-negative
control groupwithdata on smoking status, we couldnot test
for interactions between smoking and HIV, but no
interactions were found in a Danish study [12] and our
estimates of risk associated with smoking are similar towhat
has been found in HIV-negative populations [33].
We conclude that HIV-infected individuals with long-term
engagement in care may lose more life years through
smoking and associated lifestyle factors than through HIV.
Excess mortality associated with smoking increases markedly
228 AIDS 2015, Vol 29 No 2with age; therefore, increases in smoking-related mortality
can be expected as the population ages. Interventions for
smoking cessation should be prioritized.Acknowledgments
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